Aranscia https://validator.w3.org/feed/docs/rss2.html The End of the Guessing Game: Why Primary Care is Finally Ready for Pharmacogenomics Healthcare Interoperability – 2026 Health IT Predictions Healthcare at Home – 2026 Health IT Predictions The Business and Finance of Healthcare in 2026 Hospitals in 2026: Predictions for patient care, technology, and more There Seems to be No Limits on AI in Clinical Settings for 2026 InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test Virtual Healthcare in 2026: Will Congress Do Something? PGx Testing: Specialists Benefit From, and Build Upon Oncology’s Success Aranscia and Signature RX Announce Personalized Medication Management Program for GLP-1s Legal Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice AccessDx Laboratory’s Dr. Houda Hachad Named to PharmaVoice 100 Aranscia Acquires YouScript from Invitae Aranscia’s Dr. Joel Diamond Interviewed in HIMSS TV Digital Checkup Aranscia’s Joel Diamond a Featured Expert in First Report Managed Care Aranscia’s Houda Hachad a Featured Guest in DOTmed Aranscia’s Houda Hachad Interviewed in the Journal of Clinical Pathways Regarding DPYD Testing Aranscia’s Joe Spinelli Interviewed in Electronic Health Reporter Aranscia’s Houda Hachad Interviewed in the Journal of Clinical Pathways Regarding PGx Testing in Oncology Aranscia’s Houda Hachad Interviewed in the Journal of Clinical Pathways Regarding Recent FDA Safety Announcement Arancisa’s Houda Hachad Guest MedCity Influencer in MedCity News Aranscia Acquires Spesana Neurogen Biomarking Announces Partnership with Aranscia Personalized prescribing in long-term care: Why it matters more than ever PGx Can Help LTC Keep Up with Medication Oversight Evolution DPYD Safety Update: Reducing the Risk of Critical or Fatal Chemotherapy Side Effects Pharmacogenomics in Oncology: Unlocking Value, Safety, and ROI for Healthcare Systems Home